论文部分内容阅读
目的探讨Avastin在增生性糖尿病性视网膜病变(PDR)玻璃体切割手术中应用的临床效果。方法回顾分析31例(32眼)PDR患者,术前5～7d玻璃体腔内注射Avastin 0.1 mL/2.5 mg,行标准的三通道玻璃体切割手术,其中合并白内障的患者同时一期行超声乳化+人工晶体植入术。结果术中发现术前活跃的新生血管膜明显消退,术中出血明显减少,且膜剥除难度明显降低。随访3个月,26例26眼(81.3%)矫正视力较术前明显提高,4例5眼(15.6%)无明显变化,1例1眼(3.1%)视力反而下降。无严重并发症。结论Avastin可以显著降低PDR玻璃体切割手术的难度,减少术中出血,缩短手术时间,改善患者视力。但其安全性和有效性需长期大样本的临床观察。
Objective To investigate the clinical effect of Avastin in vitrectomy of proliferative diabetic retinopathy (PDR). Methods A total of 31 patients (32 eyes) with PDR were retrospectively analyzed. Intravitreal Avastin 0.1 mL / 2.5 mg was injected intraoperatively between 5 and 7 days before operation. The patients were followed up by standard three-channel vitrectomy. The patients with phacoemulsification and artificial Crystal implantation. Results Intraoperative findings of preoperative neovascularization significantly subsided, intraoperative bleeding was significantly reduced, and the difficulty of membrane stripping was significantly reduced. After 3 months of follow-up, 26 eyes (81.3%) had a significant improvement in corrected visual acuity compared with that before surgery. There were no significant changes in 4 eyes (15.6%) and decreased visual acuity in 1 patient (3.1%). No serious complications. Conclusion Avastin can significantly reduce the difficulty of PDR vitrectomy, reduce intraoperative bleeding, shorten the operation time and improve visual acuity. However, its safety and efficacy require long-term clinical observation of large samples.